Trial Profile

A Randomized, Adaptive, International Multicenter Phase 2 Study of AsiDNA in Combination with Standard of Care Chemotherapies in Non-Small Cell Lung Cancer Patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Apr 2021 New trial record
21 Apr 2021 According to an Onxeo SA media release, enrolment in this trial will start in the second half of 2021, as soon as regulatory approval is obtained.
21 Apr 2021 According to an Onxeo SA media release, the company plans to continue development of AsiDNA in combination with standard of care chemotherapies in 2021 with this randomized Phase 2 study of AsiDNA in non-small cell lung cancer. The adaptive design of this international multicenter study, currently under development, would allow its transformation into a pivotal study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com